Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.

Authors :: Matute-Blanch C
Río J
Villar LM
Midaglia L
Malhotra S
Álvarez-Cermeño JC
Vidal-Jordana A
Montalban X
Comabella M
Source :: Journal of neuroimmunology [J Neuroimmunol] 2017 Feb 15; Vol. 303, pp. 62-65. Date of Electronic Publication: 2016 Dec 18.
Publication Year :: 2017
Abstract: Chitinase 3-like 1 (CHI3L1) plays a prognostic role in patients with multiple sclerosis (MS). Here, we investigated a potential association between CHI3L1 and the response to interferon-beta (IFNβ) and glatiramer acetate (GA). Serum CHI3L1 levels were measured by ELISA in 117 relapsing-remitting MS (RRMS) patients, 76 IFNβ-treated and 41 GA-treated patients. CHI3L1 levels were increased by GA (p=0.014) but unchanged by IFNβ (p=0.830). CHI3L1 was associated with IFNβ response and levels were higher in non-responder group (p=0.020), while GA showed no responder effect (p=0.943). These results suggest a role for CHI3L1 as response biomarker to IFNβ in RRMS patients.<br /> (Copyright © 2016 Elsevier B.V. All rights reserved.)

Subjects :: Adult
Biomarkers blood
Cohort Studies
Female
Follow-Up Studies
Glatiramer Acetate pharmacology
Glatiramer Acetate therapeutic use
Humans
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting diagnosis
Prospective Studies
Treatment Outcome
Young Adult
Chitinase-3-Like Protein 1 blood
Interferon-beta therapeutic use
Multiple Sclerosis, Relapsing-Remitting blood
Multiple Sclerosis, Relapsing-Remitting drug therapy

Full Text Access

Tools